<DOC>
	<DOCNO>NCT00005044</DOCNO>
	<brief_summary>RATIONALE : Hormones stimulate growth prostate cancer cell . Hormone therapy may fight prostate cancer reduce production androgen . Radiation therapy use high-energy x-rays damage tumor cell . It yet know regimen hormone therapy radiation therapy effective prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness two different regimen hormone therapy radiation therapy treat patient prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy moderate-duration ( 28 week ) neoadjuvant total androgen suppression ( TAS ) radiotherapy ( RT ) short-duration ( 8 week ) neoadjuvant TAS RT , related disease-specific survival , patient intermediate-risk adenocarcinoma prostate . - Compare regimens , term overall survival , disease-free survival , time local tumor progression distant failure , time first biochemical failure , hormone-refractory state , treatment-induced morbidity , patient population . OUTLINE : This randomize , multicenter study . Patients stratify accord prostate-specific antigen level ( great 10 ng/mL v great 10 great 20 ng/mL v great 20 ng/mL ) , tumor stage ( T1b-2 v T3-4 ) , Gleason score ( 2-4 v 5-6 vs 7-10 ) , prior hormonal therapy ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive total androgen suppression 8 week prior initiation radiotherapy throughout radiotherapy . A luteinizing hormone-releasing hormone ( LHRH ) agonist administer every 1-3 month AND bicalutamide OR flutamide give orally daily total duration 16 week . Beginning week 9 , patient undergo radiotherapy 5 day week 8 week . - Arm II : Patients receive total androgen suppression 28 week prior initiation radiotherapy throughout radiotherapy . An LHRH agonist AND bicalutamide OR flutamide administer arm I total duration 36 week . Beginning week 29 , patient undergo radiotherapy arm I . Patients follow every 3 month 1 year , every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 1,540 patient ( 770 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Intermediate risk disease relapse determine follow combination factor : T1b4 , Gleason score 26 , prostatespecific antigen ( PSA ) great 10 great 100 ng/mL T1b4 , Gleason score 7 , PSA le 20 ng/mL T1b1c , Gleason score 810 , PSA le 20 ng/mL Must disease confirmation within 180 day study randomization Clinically negative lymph node ( N0 ) establish image negative lymph node nodal sample dissection Radiologic radioimmunoscintigraphy finding suggestive regional nodal involvement allow provide cytologic histologic evaluation show evidence neoplastic process Equivocal radiologic finding ( i.e. , maximum nodal size great 1.5 cm ) allow No distant metastasis ( M0 ) Radionuclide image finding suggestive diagnostic metastatic disease allow provide radiologic image confirm metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 0 1 Life expectancy : At least 10 year Hematopoietic : Not specify Hepatic : ALT great 2 time upper limit normal Renal : Not specify Other : Fertile patient must use effective contraception No concurrent medical illness would result life expectancy le 10 year No invasive malignancy within past 5 year except localize basal cell squamous cell skin cancer No concurrent major medical psychiatric illness would preclude study treatment followup PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : No prior androgendeprivation therapy except luteinizing hormonereleasing hormone ( LHRH ) agonist AND bicalutamide OR flutamide provide : LHRH agonist initiate 30 day study randomization bicalutamide OR flutamide initiate 14 day LHRH agonist administration No concurrent finasteride prostatic hypertrophy Radiotherapy : No prior pelvic external beam radiotherapy No prior radionuclide prostate brachytherapy No concurrent intensitymodulated radiotherapy Surgery : No prior prostatectomy No prior prostatic cryosurgery No prior bilateral orchiectomy Other : No concurrent medical research study involve prostate cancer treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>